NFE2L2 and Parkinson disease: Similarly, ACS84 outperforms NaHS in inhibiting lipid peroxidation, MAO-B [57], and mitochondrial dysfunction in Parkinson’s disease, stimulating Nrf2 and suppressing NO [58], TNF-α, and p38/JNK-MAPK in Aβ-induced microglia [59].